| Molecular formula | C207H317N45O65 |
|---|
| Molecular weight | 4476 g/mol |
|---|
| Registered trials | 44 |
|---|
| PubChem CID | 167312357 |
|---|
What Mazdutide Is
Mazdutide is an investigational peptide compound, also studied under the code names IBI362 and IBI3046. It has no approved drug label from any regulatory authority, so there are no established indications, dosing standards, or safety labeling for it. Its identity is documented in chemical databases, including a PubChem entry (CID 167312357), but this reflects chemical characterization rather than regulatory approval. Mazdutide remains a research compound studied only within clinical trial settings.
Trial Footprint
Mazdutide has been registered in 44 clinical trials to date. Sampled studies span multiple areas of investigation and stages of development. One Phase 2 trial is examining mazdutide alongside a levonorgestrel-releasing intrauterine system for fertility-sparing treatment in atypical endometrial hyperplasia or early endometrial cancer, and is not yet recruiting. A Phase 3 trial is recruiting Chinese participants with obstructive sleep apnea and a BMI of 28 kg/m2 or higher. A separate Phase 1 trial involving the related compound IBI3046 is enrolling participants with overweight or obesity and has not yet begun recruiting. These listings reflect the current scope of registered research rather than demonstrated outcomes.
FAQ
No, mazdutide has no approved label from the FDA or other regulatory authorities. It is currently studied only as an investigational compound in clinical trials.
Registered trials include research in obstructive sleep apnea with obesity, overweight or obesity in general, and fertility-sparing treatment of atypical endometrial hyperplasia or early endometrial cancer. These are active areas of investigation, not confirmed uses.
As of the most recent data, 44 clinical trials have been registered involving mazdutide, spanning multiple phases and patient populations.
IBI362 and IBI3046 are code names associated with mazdutide research programs found in clinical trial registrations. These names refer to the same investigational compound family rather than separate approved products.
No verified side effect reporting data is currently available for mazdutide, since it lacks an approved label and associated post-market safety reporting.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19